Pharmaron Beijing Co., Ltd.

Symbol: 3759.HK

HKSE

9.38

HKD

Market price today

  • 7.3919

    P/E Ratio

  • -0.4763

    PEG Ratio

  • 33.24B

    MRK Cap

  • 0.04%

    DIV Yield

Pharmaron Beijing Co., Ltd. (3759-HK) Financial Statements

On the chart you can see the default numbers in dynamics for Pharmaron Beijing Co., Ltd. (3759.HK). Companys revenue shows the average of 4689.377 M which is 0.328 % gowth. The average gross profit for the whole period is 1650.813 M which is 0.373 %. The average gross profit ratio is 0.328 %. The net income growth for the company last year performance is 0.165 % which equals 0.621 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Pharmaron Beijing Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.292. In the realm of current assets, 3759.HK clocks in at 10874.413 in the reporting currency. A significant portion of these assets, precisely 6540.899, is held in cash and short-term investments. This segment shows a change of 1.916% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 382.994, if any, in the reporting currency. This indicates a difference of 45.653% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 8784.863 in the reporting currency. This figure signifies a year_over_year change of 0.585%. Shareholder value, as depicted by the total shareholder equity, is valued at 12556.797 in the reporting currency. The year over year change in this aspect is 0.190%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2767.361, with an inventory valuation of 1013.08, and goodwill valued at 2780.92, if any. The total intangible assets, if present, are valued at 789.06. Account payables and short-term debt are 412.22 and 912.73, respectively. The total debt is 9697.59, with a net debt of 3778.68. Other current liabilities amount to 24.59, adding to the total liabilities of 13238.67. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014

balance-sheet.row.cash-and-short-term-investments

15220.46540.92242.85098.4
3852.4
4643.3
321.1
305.5
470.2
87.1
41

balance-sheet.row.short-term-investments

2674.53622745.41554.6
910
183.5
0.4
-253.9
-201
0
0

balance-sheet.row.net-receivables

10788.12767.42332.31564.9
1263.5
1033.8
733.1
590.5
457.5
276.8
245

balance-sheet.row.inventory

4119.961013.11041.5680
281.6
157.4
120.5
93.3
92.6
47.8
30.1

balance-sheet.row.other-current-assets

1955.96553.1919.41300.1
142.9
110
105.9
88.9
76.9
23.3
25.2

balance-sheet.row.total-current-assets

32084.4210874.465368643.5
5540.4
5944.5
1280.7
1078.2
1097.2
435
341.3

balance-sheet.row.property-plant-equipment-net

37650.429904.88285.85667.3
3798.7
2882.3
2376.7
2094.3
741.9
501.4
344.6

balance-sheet.row.goodwill

11046.592780.92687.92096.3
1166.2
203.3
139.9
133.5
0
0
0

balance-sheet.row.intangible-assets

3208.94789.1802.5692.9
566.1
420.6
389.9
302
21.8
21.5
22

balance-sheet.row.goodwill-and-intangible-assets

14255.5335703490.42789.2
1732.2
623.9
529.8
435.5
21.8
21.5
22

balance-sheet.row.long-term-investments

1234.35383262.9-792
-508.3
6.8
52.5
257.2
204.5
141.4
154.6

balance-sheet.row.tax-assets

514.73153.258.815.6
8.4
6.4
6.2
7.6
5.7
6.9
9.2

balance-sheet.row.other-non-current-assets

6650.921591.31858.72065.4
1337.3
471.2
379.7
46.4
733.5
68.3
59.8

balance-sheet.row.total-non-current-assets

60305.9515602.313956.69745.6
6368.4
3990.6
3344.8
2841
1707.4
739.5
590.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0

balance-sheet.row.total-assets

92390.3826476.720492.618389.1
11908.8
9935
4625.5
3919.2
2804.6
1174.5
931.5

balance-sheet.row.account-payables

1658.32412.2406.3315.5
191.5
118
108.2
91.6
61.3
41.5
26.8

balance-sheet.row.short-term-debt

3378.6912.7901.7577.6
470.1
364.8
539.8
471.7
309.7
208.2
183.8

balance-sheet.row.tax-payables

897.87237.9188.3114.2
51.8
43.7
31.1
35.1
13.4
11.6
10.2

balance-sheet.row.long-term-debt-total

24769.118784.95214.84707.5
581.4
673.2
876.1
829.5
315
3
5.5

Deferred Revenue Non Current

1181.91391.7152.4149.4
158.1
111.6
101
63.9
14
14.6
17

balance-sheet.row.deferred-tax-liabilities-non-current

1080.85---
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

265724.62604.313.8
1320.2
150.9
576.6
106.9
83.5
44.4
26.5

balance-sheet.row.total-non-current-liabilities

27499.39584.25740.35111.8
993.3
827.3
1027.8
967.9
380.3
41
92.7

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

2595.21585.2760.5284.3
186.6
131.2
145.2
0
0
0
0

balance-sheet.row.total-liab

42844.1313238.79652.78093.8
2975.1
2097
2283.6
1908.9
1041.1
1006.1
673.2

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0

balance-sheet.row.common-stock

6552.081787.41191.2794.2
794.4
794.4
590.7
590.7
590.7
131
125

balance-sheet.row.retained-earnings

19220.425204.54152.43221.8
1929
962.2
548.3
241
37.9
-91.6
-165.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
-665.1
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

21203.995564.952056113.3
6146.9
6010.5
1855.1
1166
1134.9
129.1
298.7

balance-sheet.row.total-stockholders-equity

46976.4912556.810548.610129.2
8870.3
7767.1
2328.9
1997.7
1763.4
168.4
258.2

balance-sheet.row.total-liabilities-and-stockholders-equity

92390.3826476.720492.618389.1
11908.8
9935
4625.5
3919.2
2804.6
1174.5
931.5

balance-sheet.row.minority-interest

2569.75681.2291.3166.1
63.4
71
13
12.6
0
0
0

balance-sheet.row.total-equity

49546.251323810839.910295.3
8933.7
7838
2341.9
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

92390.38---
-
-
-
-
-
-
-

Total Investments

3908.8810051008.3762.7
401.7
190.3
52.9
3.3
3.5
141.4
154.6

balance-sheet.row.total-debt

28147.719697.66116.55285.1
1051.5
1038
1415.9
1301.2
624.7
211.2
189.3

balance-sheet.row.net-debt

15601.843778.746191741.3
-1890.9
-3421.9
1095.2
995.7
154.5
124.1
148.2

Cash Flow Statement

The financial landscape of Pharmaron Beijing Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.861. The company recently extended its share capital by issuing 0, marking a difference of 50.047 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -2250832788.120 in the reporting currency. This is a shift of 0.019 from the previous year. In the same period, the company recorded 927.17, -0.67, and -559.14, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -444.79 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 4919.19, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014

cash-flows.row.net-income

1139.041581.81352.11620.1
1147
530.7
339
227
176.9
73.8
21

cash-flows.row.depreciation-and-amortization

0927.2696.2497.9
375.2
317.7
211.7
144.6
92.9
63.7
51.3

cash-flows.row.deferred-income-tax

-145.150-177.2-67.5
-62.5
-11.5
0
0
0
0
5.3

cash-flows.row.stock-based-compensation

145.210177.267.5
62.5
11.5
0
0
0
0
8.2

cash-flows.row.change-in-working-capital

00-346.5130
234.6
-61.1
43.1
66.7
-106.8
1.4
-109.2

cash-flows.row.account-receivables

00-830.6-295.7
-95.3
-278.1
0
0
0
0
0

cash-flows.row.inventory

082.4-120.9-224.9
-120
-38
-28.3
-1.4
-45.6
-18.4
-13.4

cash-flows.row.account-payables

00830.6295.7
95.3
278.1
0
0
0
0
0

cash-flows.row.other-working-capital

0-82.4-225.6354.9
354.6
-23.2
71.4
68.1
-61.2
19.8
-95.8

cash-flows.row.other-non-cash-items

708.42244.6441-190
-108.1
151.4
143.5
113.9
72.7
78
35.7

cash-flows.row.net-cash-provided-by-operating-activities

2571.65000
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-2865.32-2865.3-2949.9-2092.8
-1315.8
-754.6
-641
-934.7
-1055.5
-258.3
-81.9

cash-flows.row.acquisitions-net

08.1-1021.8-1230.5
-791.5
-59.5
0
-345.6
-80.7
-222.6
0

cash-flows.row.purchases-of-investments

-2113.17-2113.2-2336-4928.2
-2635.7
-693.9
-96
0
-3.3
0
0

cash-flows.row.sales-maturities-of-investments

2720.212720.240962987.9
1390.6
491.3
0
0
1055.9
0
0

cash-flows.row.other-investing-activites

7.45-0.73.25.5
-18.5
-28.5
22.4
0.4
-1055.5
0.1
0

cash-flows.row.net-cash-used-for-investing-activites

-2250.83-2250.8-2208.5-5258.1
-3371.1
-1045.2
-714.6
-1279.9
-1139.1
-480.9
-81.9

cash-flows.row.debt-repayment

-559.14-559.1-612.6-158.6
-761
-1289.3
-423.7
-219.8
-147.5
-138.2
-108.6

cash-flows.row.common-stock-issued

860.830393.4284.1
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-860.830-393.4-284.1
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-444.79-444.8-404.8-284.7
-135.4
-143.2
-74.6
-60.6
-14.4
-15.9
-14.9

cash-flows.row.other-financing-activites

4919.194919.2-399.94104.7
616.2
5678.4
482.7
852.7
1442.9
452.3
165.6

cash-flows.row.net-cash-used-provided-by-financing-activities

3915.263915.3-1417.33661.4
-280.2
4245.9
-15.6
572.2
1281
298.1
42.1

cash-flows.row.effect-of-forex-changes-on-cash

11.4311.473-45.5
-85.7
-4.3
6.5
-12.9
9.3
2.6
0.9

cash-flows.row.net-change-in-cash

4429.44429.4-1410415.8
-2088.3
4135
13.6
-168.3
387
36.8
-26.8

cash-flows.row.cash-at-end-of-period

12278.015789.11359.72769.7
2353.9
4442.2
307.2
293.6
461.9
75
38.2

cash-flows.row.cash-at-beginning-of-period

7848.611359.72769.72353.9
4442.2
307.2
293.6
461.9
75
38.2
65

cash-flows.row.operating-cash-flow

2571.652753.52142.82058
1648.6
938.6
737.3
552.2
235.8
216.9
12.1

cash-flows.row.capital-expenditure

-2865.32-2865.3-2949.9-2092.8
-1315.8
-754.6
-641
-934.7
-1055.5
-258.3
-81.9

cash-flows.row.free-cash-flow

-293.67-111.8-807-34.8
332.8
184
96.3
-382.5
-819.7
-41.4
-69.8

Income Statement Row

Pharmaron Beijing Co., Ltd.'s revenue saw a change of 0.124% compared with the previous period. The gross profit of 3759.HK is reported to be 4124.48. The company's operating expenses are 2291.16, showing a change of 13.547% from the last year. The expenses for depreciation and amortization are 927.17, which is a 0.003% change from the last accounting period. Operating expenses are reported to be 2291.16, which shows a 13.547% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.093% year-over-year growth. The operating income is 1847.89, which shows a 0.093% change when compared to the previous year. The change in the net income is 0.165%. The net income for the last year was 1601.1.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014

income-statement-row.row.total-revenue

115381153810266.37443.8
5133.6
3757.2
2908.1
2294.1
1634.2
1128
790.4

income-statement-row.row.cost-of-revenue

7413.517413.56497.94764.9
3210.1
2422.8
1963.5
1543.1
1160.2
817.6
592.1

income-statement-row.row.gross-profit

4124.484124.53768.42678.9
1923.5
1334.4
944.7
751
474
310.4
198.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0

income-statement-row.row.research-development

448.28---
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

752.13---
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

252.78---
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

36.3833.1766591.8
345.3
272
20.5
15.5
24.7
14.6
6.1

income-statement-row.row.operating-expenses

2291.162291.22017.81154.1
838.9
630.2
503.5
388.9
286
225
156.9

income-statement-row.row.cost-and-expenses

9704.679704.78515.75918.9
4049
3053
2467
1932
1446.2
1042.6
749

income-statement-row.row.interest-income

33.5433.535.264.4
74.1
9.6
0.4
0.4
1.8
1.2
0

income-statement-row.row.interest-expense

182.19182.2167.383.1
23.9
82.5
71.6
60.3
17.5
17.1
13.4

income-statement-row.row.selling-and-marketing-expenses

252.78---
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-10.01-10-23.5-3.3
-4.5
1.1
-40.6
-83.6
26.5
2.1
-12.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

36.3833.1766591.8
345.3
272
20.5
15.5
24.7
14.6
6.1

income-statement-row.row.total-operating-expenses

-10.01-10-23.5-3.3
-4.5
1.1
-40.6
-83.6
26.5
2.1
-12.6

income-statement-row.row.interest-expense

182.19182.2167.383.1
23.9
82.5
71.6
60.3
17.5
17.1
13.4

income-statement-row.row.depreciation-and-amortization

240.91927.2924.5682.9
305.9
393.1
211.7
144.6
92.9
63.7
51.3

income-statement-row.row.ebitda-caps

2088.8---
-
-
-
-
-
-
-

income-statement-row.row.operating-income

1847.891847.91689.91914.3
1323.8
631.5
380
263
189.8
72.9
24.6

income-statement-row.row.income-before-tax

1837.891837.91666.41911
1319.4
632.6
400.5
278.5
214.5
87.5
28.9

income-statement-row.row.income-tax-expense

256.11256.1314.3290.9
172.4
101.9
61.5
51.5
37.6
13.7
7.9

income-statement-row.row.net-income

1601.11601.11374.61661
1172.4
547.2
339.2
230.9
176.9
73.8
21

Frequently Asked Question

What is Pharmaron Beijing Co., Ltd. (3759.HK) total assets?

Pharmaron Beijing Co., Ltd. (3759.HK) total assets is 26476712835.000.

What is enterprise annual revenue?

The annual revenue is 5897878192.000.

What is firm profit margin?

Firm profit margin is 0.357.

What is company free cash flow?

The free cash flow is -0.216.

What is enterprise net profit margin?

The net profit margin is 0.139.

What is firm total revenue?

The total revenue is 0.160.

What is Pharmaron Beijing Co., Ltd. (3759.HK) net profit (net income)?

The net profit (net income) is 1601096033.000.

What is firm total debt?

The total debt is 9697590579.000.

What is operating expences number?

The operating expences are 2291155235.000.

What is company cash figure?

Enretprise cash is 5918915276.000.